Day: June 25, 2025

– End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled – – Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies – PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025. During the meeting, the Cognition team will review results of the Phase 2 ‘SHINE’ study (NCT03507790) of zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease. In addition, proposed plans for a Phase 3 program designed to support regulatory approval of zervimesine in this patient population will...

Flipping the script on the traditional dispensary format, the new bodega-style shopping experience offers customers the freedom to browse and select their favorite items directly from shelves featuring one of the largest assortments of directly accessible cannabis products in the U.S. Verano will host a grand re-opening weekend-long Summer Festival celebration at Zen Leaf Cave Creek featuring giveaways, local artisan pop-ups, food trucks, and meet-and-greets with rap icons Dizzy Wright and Devin the Dude on June 28thVerano will explore scaling the new bodega-style dispensary experience across the Company’s entire Arizona retail footprint, and will offer third-party wholesale partners in-store activation opportunities in the near future The Company’s vertical Arizona operations consist of multiple cultivation and processing facilities,...

Highlights:Six diamond drillholes are planned to target the auriferous veins historically mined from the Foley Mine shaft. Drilling commenced on Wednesday, June 18, 2025, following receipt of permits and a site inspection conducted by the Nigigoonsiminikaaning First Nation. First hole intersected 1.5m of quartz vein with pyrite, chalcopyrite, sphalerite and galena.Q-Gold Resources Ltd. (TSXV: QGR) Commences Phase 3 Diamond Drilling Program at Foley Shaft, Mine Centre Project, Northwestern Ontario TORONTO, June 25, 2025 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd. (TSXV: QGR) (“Q-Gold” or the “Company”) is pleased to announce the commencement of its Phase 3 diamond drilling program at the historic Foley Shaft, part of its Mine Centre Project located in northwestern Ontario. The drill program is the first step in a 4-stage exploration...

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that it has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical, one of the leading pharmaceutical companies in China. The parties have mutually agreed to conclude the strategic partnership entered into in 2021 for development, manufacturing and commercialization of imdusiran in mainland China, Hong Kong, Macau and Taiwan markets. “I would like to express our deepest thanks...

VANCOUVER, BC, June 25, 2025 (GLOBE NEWSWIRE) — Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: EATBF) (FSE: 988) (“Digital Asset Technologies” or the “Company”), a technology focused investment issuer, is pleased to announce that its portfolio company LiquidLink AI Corp. (“LinkLink”), will host a new weekly series of X (formerly Twitter) Spaces dedicated to exploring the future of Real World Assets (RWAs) on the XRP Ledger and the Bitcoin Lightning Network. The series will launch on Monday, July 7 at 11:00 AM EST, and will continue every Monday at the same time via the official LiquidLink X account: @LiquidLink_XRP. Each week, LiquidLink will host live discussions featuring developers, asset issuers, legal experts, and ecosystem builders to explore topics such as: ●How RWAs are issued and traded on the XRP Ledger ‎●Infrastructure...

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 25, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, the Company’s proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD). The first patient was enrolled at Yale School of Medicine’s Department of Psychiatry, marking a significant milestone in the trial. The trial is evaluating the safety,...

On 12 June 2025 the general meeting of shareholders of Hepsor AS, registry code 12099216 (hereinafter the Company) adopted a resolution without convening the meeting to amend the Company’s articles of association and adopt the articles of association in the new wording. Today, on 25 June 2025 the amended articles of association were registered at the Estonian Commercial Register and the new articles of association entered into force. The articles of association are attached to this stock exchange announcement and are also available on the webpage of the Company on https://hepsor.ee/en/for-investors/corporate-governance/bylaws/. Additional information:  Henri Laks Member of the management board Tel: +372 5693 9114 E-mail: henri@hepsor.eeHepsor AS (www.hepsor.ee) is a developer of residential and commercial real estate. The Group operates...

WILMINGTON, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN, OTCQB: LDDFF, FSE:E30), a leading technology provider of AI-based next generation detection solutions for concealed weapons and threats, is pleased to announce that The Honorable Thomas Monheim, former Inspector General for the US Intelligence Community and current Executive Director, Global Compliance Investigations and Ombuds, for GE Aerospace, has joined our new Strategic Advisory Board which will have up to nine Members. This new Board will help focus and guide Liberty Defense in its journey to scale its groundbreaking technology, both in the United States and globally. Tom Monheim dedicated more than three decades of service to the United States, beginning as a Judge Advocate in the US Air Force and finally...

VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) — Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”), is pleased to announce the voting results for the election of its Board of Directors at the Annual General Meeting (“AGM”) of Shareholders held virtually on June 24, 2025 (the “Meeting”). The director nominees, as listed in the Company’s Information Circular dated May 14, 2025, and SEDAR+ filed May 16, 2025, were elected as directors of the Company at the Meeting to serve until the next AGM. A total of 79,766,163 of the Company’s common shares (“Common Shares”) were present or represented by proxy at the Meeting, representing 44.99% of the outstanding Common Shares. The voting results for the election of directors are as follows: Election of Directors:Name of Nominee VotesFor VotesFor...